Opportunity and Strategy Analysis
This report focuses on identifying opportunities and strategies for investing in the global tumor ablation market within the forecast period. It provides a complete analysis of the global market both quantitatively and qualitatively. The quantitative analysis includes market size and revenue data of the total demand, sub-markets, and regional/national levels throughout 2023-2033. Qualitative analysis depicts a full picture of market dynamics and trends including drivers, restraints and challenges, emerging products/market trends, and Porter’s Fiver Forces analysis.
Based on the market data and analysis, the report highlights Increasingly Attractive Segments (IAS) and business opportunities in each segmentation. Moreover, a systematic evaluation of Internal Risks (factors arising within the industry development) and External Risks (factors arising from the surrounding environments) is provided for the tumor ablation industry and market. All the identified risk factors are measured quantitatively according to GMD’s novel numeric system, i.e. each risk is evaluated with GMD Risk Index Number (GMD RIN) and GMD Risk Intensity Level (GMD RIL). This in-depth risk assessment offers a comprehensive understanding of the current risk factors and their developing trends. Furthermore, this report concludes risk management strategies and Critical Success Factors (CSFs) to help companies make intelligence-based business decisions in the global tumor ablation industry.
Market Coverage & Overview
The report is based on studies for 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. Considering impact of COVID-19 and regional conflicts such as Russia-Ukraine war, the trend and outlook of global market is forecast in optimistic, balanced, and conservative scenarios. In the balanced view, the global tumor ablation market is expected to reach $4.79 billion by 2033, growing by 12.4% annually over the coming years.
Segmentation Analysis
Highlighted with 88 tables and 98 figures, this 187-page report represents a 360-degree view on the global market with extensively detailed segmentations Technology, Component, Treatment, Application, End User, and Region/Country as shown below. Annual revenue 2023-2033 for each segment is included in the report.
By Technology
• Radiofrequency Ablation
• Microwave Ablation
• Irreversible Electroporation Ablation
• Cryoablation
• High-Intensity Focused Ultrasound
• Other Technologies
By Component
• Generators
• Probes/Electrodes
By Treatment
• Surgical Ablation
• Percutaneous Ablation
• Laparoscopic Ablation
By Application
• Lung Cancer
• Kidney Cancer
• Liver Cancer
• Breast Cancer
• Bone Cancer
• Prostate Cancer
• Other Applications
By End User
• Hospital and Clinics
• Specialty Centers
• Other End Users
By Region
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Colombia, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
The breakdown of all regional markets by country and the breakdown of each national market by Technology, Treatment, and Application over the forecast years are also included.
Key Companies
The report also covers the current competitive scenario and profiles key vendors including market leaders and important emerging players. A selection of companies profiled in this report includes:
• AngioDynamics Inc.
• Biotronik
• Bioventus Inc. (Misonix Inc.)
• Boston Scientific Corporation
• Chongqing Haifu Medical Technology Co., Ltd.
• CONMED Corporation
• EDAP TMS
• Ethicon, Inc. (Johnson & Johnson)
• HealthTronics, Inc.
• HistoSonics, Inc.
• IceCure Medical Ltd.
• Integra Life Science Holding Corporation
• Medtronic plc
• Mermaid Medical Group
• Olympus Corporation
• Smith & Nephew PLC
• Sonacare Medical